
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Review |
Authors' Affiliations: 1 CHU Montpellier, Institut de Recherche en Biothérapies, Hôpital Saint-Eloi; 2 Institut National de la Sante et de la Recherche Medicale, U847; 3 Université Montpellier1, UFR de Médecine; 4 CHU Montpellier, Service d'Hématologie et d'Oncologie Médicale, Montpellier, France; and 5 Medizinische Klinik und Poliklinik V, Universitätsklinikum Heidelberg, Germany
Requests for reprints: Bernard Klein, Institut de Recherche en Biothérapies, CHU Montpellier, Hôpital Saint-Eloi, Av Augustin Fliche, Montpellier F-34285, France. Phone: 33-4-67-33-78-88; Fax: 33-4-67-33-70-05; E-mail: klein{at}montp.inserm.fr.
Multiple myeloma is a B-cell neoplasia characterized by the proliferation of a clone of malignant plasma cells in the bone marrow. We review here the input of gene expression profiling of myeloma cells and of their tumor microenvironment to develop new tumor classifiers, to better understand the biology of myeloma cells, to identify some mechanisms of drug sensitivity and resistance, to identify new myeloma growth factors, and to depict the complex interactions between tumor cells and their microenvironment. We discuss how these findings may improve the clinical outcome of this still incurable disease.
This article has been cited by other articles:
![]() |
G. C. Prendergast Metastasis, miRNAs, Multiple Myeloma, and More Cancer Reviews Online Content, January 1, 2008; 2008(1): 1 - 1. [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |